Finally, BYLieve supports the notion that the PIK3Ca inhibitor alpelisib is a reasonable treatment option in patients with PIK3Ca mutant luminal breast cancer progressing on CDK4/6-inhibitor therapy. Here, CDK4 is linked to breast cancer.